CONMED Corporation
CNMD Healthcare Medical Devices
CONMED Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 5.18% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 11.6%, free cash flow grew 46.0% and total debt fell 5.40%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five, operating cash flow growth for three.
Follow CNMD
CONMED Corporation (CNMD) Piotroski F-score
CONMED Corporation's Piotroski F-score for fiscal 2025 is 5 out of 9: 5 of nine tests of profitability, leverage and efficiency passed, down from 8 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 5 | (3.00) |
| FY2024 | 8 | 1.00 |
| FY2023 | 7 | 5.00 |
| FY2022 | 2 | (6.00) |
| FY2021 | 8 | 3.00 |
| FY2020 | 5 | 1.00 |
| FY2019 | 4 | (2.00) |
| FY2018 | 6 | 0.00 |
| FY2017 | 6 | 2.00 |
| FY2016 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 2.03% | 5.75% | Pass | 1 |
| Positive operating cash flow | 170.69m | 166.97m | Pass | 1 |
| Rising return on assets | 2.03% | 5.75% | Fail | 0 |
| Cash flow above net income | 123.63m | 34.55m | Pass | 1 |
| Falling long-term leverage | 0.36 | 0.39 | Pass | 1 |
| Rising current ratio | 2.14 | 2.30 | Fail | 0 |
| No new shares issued | 31,036,000 | 30,846,000 | Fail | 0 |
| Rising gross margin | 54.59% | 56.08% | Fail | 0 |
| Rising asset turnover | 0.59 | 0.57 | Pass | 1 |
| Piotroski F-score | Mixed | 5 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| BVS Bioventus Inc. compare | 8 |
| AORT Artivion, Inc. compare | 7 |
| ATEC Alphatec Holdings, Inc. compare | 6 |
| IRMD iRadimed Corporation compare | 6 |
| CNMD CONMED Corporation | 5 |
| ESTA Establishment Labs Holdings Inc. compare | 5 |
| ENOV Enovis Corporation compare | 4 |
| NVCR NovoCure Limited compare | 4 |
| TNDM Tandem Diabetes Care, Inc. compare | 3 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover